VENCLEXTA is a first-in-class treatment that targets BCL-2 to help restore the process of apoptosis 1

  • The ability to evade apoptosis is an important hallmark of cancer. Overexpression of BCL-2 has been demonstrated in CLL cells and has been associated with resistance to chemotherapy 1,3
  • Overexpressed BCL-2 allows CLL cells to evade apoptosis by sequestering
    pro-apoptotic proteins 1
  • VENCLEXTA selectively binds to BCL-2, displacing pro-apoptotic proteins and triggering events that lead to apoptosis 1

Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes 2

  • Upon binding to CD20, rituximab mediates B-cell lysis
  • Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC)

CLL=chronic lymphocytic leukemia; BCL-2=B-cell lymphoma 2.